Sandoz Expects Imminent US Pegfilgrastim Action
Seven Months Have Passed Since Refiling With FDA
Executive Summary
Sandoz chief Richard Saynor remains confident in the firm’s US pegfilgrastim filing, even though it has been with the FDA for more than six months.
You may also be interested in...
Sandoz Gets Approval For US Pegfilgrastim
Sandoz has finally received a much-awaited FDA approval for its pegfilgrastim biosimilar, Ziextenzo, which will be launched in the US “as soon as possible this year.”
Kanjinti and Mvasi Make ‘Solid Start’ In US
Launching its Kanjinti and Mvasi trastuzumab and bevacizumab biosimilars ‘at risk’ in July generated third-quarter sales of $81m for Amgen, contributing nearly half of global biosimilar turnover of $173m.
Sandoz And Polpharma Strike Global Deal For Natalizumab
Polpharma and Sandoz have stuck a global licensing deal that gives the Novartis subsidiary rights to market the Polish firm’s biosimilar natalizumab rival to Biogen’s Tysabri.